Online inquiry

IVTScrip™ mRNA-Anti-S, REGN-10933(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13787MR)

This product GTTS-WQ13787MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets S gene. The antibody can be applied in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq YP_009724390.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 43740568
UniProt ID P59594
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-S, REGN-10933(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13787MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12115MR IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MORAb-003
GTTS-WQ14154MR IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA aIL6R88
GTTS-WQ12297MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MSB-0010718C
GTTS-WQ3502MR IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BAN-2401
GTTS-WQ7430MR IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GBR500
GTTS-WQ4791MR IVTScrip™ mRNA-Anti-DPP4, BT 5/9(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BT 5/9
GTTS-WQ4695MR IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-986168
GTTS-WQ10935MR IVTScrip™ mRNA-Anti-HAVCR2, MBG-453(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MBG-453
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW